Zoe c Venables

Dr. Zoe c Venables

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 March 2019 in British Journal of Dermatology
Verified
Journal Article
Open access
PDF file
ZVZ.C. Venables
Z.C. Venables
TNT. Nijsten
T. Nijsten
KWK.F. Wong
K.F. Wong
PAP. Autier
P. Autier
JBJ. Broggio
J. Broggio
ILI.M. Leigh
I.M. Leigh
Background Basal cell carcinoma (BCC) and cutaneous squamous cell carcinoma (cSCC), together known as keratinocyte cancers (KCs), are the commonest cancer in Caucasian populations. Recent improvements to registry data collection in England has allowed more accurate analysis of the epidemiology of BCC and cSCC and for the first time we are able to provide an accurate (representative) tumour burden for KC in the UK. Objective To estimate the incidence of BCC and cSCC in the UK. Methods A cohort of patients with KCs between 2013 and 2015 were identified using linkage to diagnostic codes derived from pathology reports collected into the national cancer registry. Data from England's cancer registry were combined with data from Scotland, Northern Ireland and Wales. European Age Standardised incidence rates (EASRs) of the first BCC and cSCC per patient per annum (PPPA) were calculated. Results In the UK, the EASR of the first BCC and cSCC PPPA 2013‐2015 were 285 and 77 per 100,000 person‐years respectively (211,120 KCs total in 2015). The mean annual percentage increase was 5% between 2013‐2015 for both BCC and cSCC. By counting the first tumour per patient per year, we include an additional 51% KCs compared to the previous reporting technique which counts only the first BCC and cSCC in a patient's lifetime, yet it represents a probable underestimation of 5‐11% of the true tumour count. Conclusions Based on an improved methodology, a more representative incidence of KC is presented, which is essential to healthcare planning and will lead to improved understanding of the epidemiology of KC.

23 February 2023 in British Journal of Dermatology
Verified
Journal Article
Open access
PDF file
BBBirgitta van Bodegraven
Birgitta van Bodegraven
SVSally Vernon
Sally Vernon
CECharlotte Eversfield
Charlotte Eversfield
RBRuth Board
Ruth Board
PCPaul Craig
Paul Craig
ZVZoe Venables
Zoe Venables
Background: Providing detailed skin cancer statistics, including incidence and survival, by tumour type and patient characteristics is important for up-to-date epidemiological information. Objectives: To create a new clinically relevant consensus-based classification for registered skin tumours using tumour type and patient characteristics and to describe its application to all registered tumours in England between 2013 and 2019. Methods: Tumours with skin topographical codes (ICD-10) and morphology and behaviour (ICD-O3) were grouped together in an iterative process creating a hierarchical tree structure. The primary-level grouping partitioned skin tumours into skin cancer, melanoma in situ, extramammary Paget disease (EMPD) and tumours of uncertain malignant potential. Second-level groups split skin cancer into keratinocyte cancer (KC), melanoma and rare cancers. The third-level group split KC into basal cell carcinoma (BCC) and squamous cell carcinoma (cSCC). Further groups were split into genital or non-genital, first or subsequent tumour, age, gender, stage, or National Health Service (NHS) region. Incidence counts, Kaplan–Meier and net survival estimates and referral routes [two-week wait (TWW), general practitioner (GP), outpatient] categorisations were calculated for each grouping across all years. Results: A total of 1 445 377 skin cancers and 49 123 precancerous lesions and undefined entities were registered in England between 2013 and 2019. Skin tumours and skin cancer incidence rates are increasing for most tumour types. The most common type of skin cancer was BCC with an incidence rate of 282.36 per 100 000 person-years (PYs) [n = 158 934, 95% confidence interval (CI) 280.98–283.76] in 2019, followed by cSCC with an incidence rate of 85.24 per 100 000 PYs (n = 47 977, 95% CI 84.48–86.00) and melanoma with 27.24 (n = 15 332, 95% CI 26.81–27.67) per 100 000 PYs. Each year approximately 1800 rare skin cancers, 1500 genital cSCCs and 100 cases of EMPD are registered. Of 15 000 melanoma cases, 120 cases of melanoma occur in individuals aged < 25 years annually. One-year and five-year overall net survival varies by tumour type. cSCC 5-year net survival (89.8%, 95% CI 88.8–90.9) was comparable to the net survival of all melanomas (89.6%, 95% CI 88.7–90.6). BCC had excellent survival (overall net survival > 100%). Patients with late-stage melanoma, Merkel cell carcinoma and genital cSCC have a 5-year net survival < 60%. Older patients received fewer TWW referrals than their younger counterparts with the same tumour type at the same location. Patients with acral lentiginous melanoma had fewer TWW referrals and more standard GP referrals than patients with common melanomas. Conclusions: ‘Get Data Out’ Skin provides detailed and up-to-date statistics on all registrable skin tumours in England, including for the first time precancerous lesions and rare subtypes of common cancers. These data can be used by clinicians, researchers and commissioners to better understand skin cancer and improve resource allocation.

26 March 2022 in British Journal of Dermatology
Verified
Journal Article
Open access
PDF file
ZVZoe Claire Venables
Zoe Claire Venables
STSelin Tokez
Selin Tokez
LHLoes M. Hollestein
Loes M. Hollestein
AMAntien Mooyaart
Antien Mooyaart
RBRenate Ruth van Den Bos
Renate Ruth van Den Bos
MWMarlies Wakkee
Marlies Wakkee
Background Cutaneous squamous cell carcinoma (cSCC) is the second most common cancer worldwide with relatively low metastatic potential (2-5%). Developments in therapeutic options have highlighted the need to better identify high-risk patients who could benefit from closer surveillance, adjuvant therapies, and baseline/follow-up imaging, while at the same time safely omitting low-risk patients from further follow-up. Controversy remains regarding the predictive performance of current cSCC staging systems and which methodology to adopt. Objectives To validate the performance of four cSCC staging systems (American Joint Committee on Cancer 8th edition (AJCC8), Brigham and Women’s Hospital (BWH), Tübingen, and Salamanca T3 refinement) in predicting metastasis using a nationwide cohort. Methods A nested case-control study using data from the National Disease Registration Service, England, 2013-2015 was conducted. Metastatic cSCC cases were identified using an algorithm to identify all potential cases for manual review. These were 1:1 matched on follow-up time to non-metastatic controls randomly selected from 2013. Staging systems were analyzed for distinctiveness, homogeneity, monotonicity, specificity, positive predictive value (PPV), negative predictive value (NPV), and c-index. Results 887 metastatic cSCC cases and 887 non-metastatic cSCC controls were included. BWH showed highest specificity (92.8%, 95% confidence interval (CI) 90.8-94.3%), PPV (13.2%, 95% CI 10.6-16.2%), and c-index (0.84, 95% CI 0.82-0.86). AJCC8 showed superior NPV (99.2%, 95% confidence interval (CI) 99.2-99.3), homogeneity and monotonicity compared with BWH and Tübingen diameter and thickness classifications (p<0.001). Salamanca refinement did not show any improvement in AJCC8 T3 cSCC staging. Conclusions We validated four cSCC staging systems using the largest nationwide dataset of metastatic cSCC so far. Although BWH showed the highest overall discriminative ability, PPV was low for all staging systems, which shows the need for further improvement and refining of current cSCC staging systems.

18 August 2021 in Skin Health and Disease
Verified
Journal Article
Open access
PDF file
MKM. Kwiatkowska
M. Kwiatkowska
SAS. Ahmed
S. Ahmed
MAM. Ardern-Jones
M. Ardern-Jones
LBL. A. Bhatti
L. A. Bhatti
TBT. O. Bleiker
T. O. Bleiker
ZVZ. C. Venables
Z. C. Venables
Introduction: The most common cancers in the UK are keratinocyte cancers (KCs): the combined term for basal cell carcinomas (BCCs) and cutaneous squamous cell carcinomas (cSCCs). Registration of KC is challenging due to high numbers and multiplicity of tumours per person. Methods: We provide an updated report on the descriptive epidemiology of trends in KC incidence for the resident populations of UK countries (England, Northern Ireland, Scotland and Wales) using population-based cancer registry and pathology report data, 2013–18. Results: Substantial increases in cSCC incidence in England, Scotland and Northern Ireland can be detected for the period of 2013–18, and the incidence of cSCC also increased in Wales from 2016 to 2018. In contrast, however, the pattern of annual change in the incidence of BCC across the nations differs. In England, the incidence of BCC declined slightly from 2016 to 2018, however, the overall trend across 2013–18 is not statistically significant. In Scotland, the incidence of BCC shows some variability, declining in 2017 before increasing in 2018, and the overall trend across 2013–18 was also not statistically significant. In Northern Ireland, the incidence of BCC increased significantly over the study period, and in Wales, the incidence of BCC increased from 2016 to 2018. One in five people will develop non-melanoma skin cancers (NMSC) in their lifetime in England. This estimate is much higher than the lifetime risk of melanoma (1 in 36 males and 1 in 47 females born after 1960 in the UK), which further highlights the burden of the disease and importance of early prevention strategies. Conclusions: We highlight how common these tumours are by publishing the first ever lifetime incidence of NMSC. Additionally, the first time reporting of the age standardised incidence of KC in Wales further confirms the scale of the disease burden posed by these cancers in the UK. With approximately one in five people developing NMSC in their lifetime, optimisation of skin cancer prevention, management and research are essential.

3 May 2021 in British Journal of Dermatology
Verified
Journal Article
Open access
PDF file
ZVZ. C. Venables
Z. C. Venables
SAS. Ahmed
S. Ahmed
TBT. O. Bleiker
T. O. Bleiker
JBJ. Broggio
J. Broggio
MKM. Kwiatkowska
M. Kwiatkowska
SMS. McPhail
S. McPhail
The first UK national COVID‐19 lockdown began 23rd March 2020. Immediately, almost all outpatient healthcare service requests temporarily focused exclusively on urgent referrals and two‐week‐wait urgent cancer referrals with restrictions due to staff sickness, redeployment and changing work environments. Additionally, patient anxiety regarding attending appointments and perceived overburdening of healthcare resources resulted in fewer presentations.2 Technological advancements have arisen from challenging circumstances. The National Cancer Registration and Analysis Service (NCRAS), England, has developed a Rapid Cancer Registration Dataset (RCRD). Utilising automated datafeeds, lag‐time from diagnosis to registration is reduced from 18 to 4 months, however, data has not been quality assured to the same standards and completeness.4 We identify how the pandemic has affected skin cancer.

11 February 2022 in Clinical and Experimental Dermatology
Verified
Journal Article
Closed access
PDF file
JJJilse Joshy
Jilse Joshy
KMKhaylen Mistry
Khaylen Mistry
NLNick J. Levell
Nick J. Levell
BBBirgitta Bodegraven
Birgitta Bodegraven
SVSally Vernon
Sally Vernon
ZVZoe Claire Venables
Zoe Claire Venables